Andrx Receives FDA Approval for Generic Tiazac; Launch Underway.

Business Editors/Health/Medical Writers

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--April 10, 2003

Andrx Corporation (Nasdaq:ADRX) today announced that the United States Food and Drug Administration (FDA) has approved the marketing of its Abbreviated New Drug Application (ANDA), for the 120 mg., 180 mg., 240 mg., 300 mg., and 360 mg. strengths of its Diltiazem Hydrochloride Extended-release Capsules that are bioequivalent to Tiazac(R). To be marketed under the name Taztia(TM), this product is a calcium channel blocker indicated for the treatment of hypertension and chronic stable angina. Tiazac is manufactured by Biovail Corporation, marketed by Forest Laboratories, Inc., and had 2002 U.S. sales of $270 million.

Richard J. Lane, Andrx's Chief Executive Officer, remarked: "I am exceedingly pleased to announce this approval which we have anticipated receiving for a long time. Although we have maintained that our product was bioequivalent and stable, receiving final FDA approval ends all speculation. Simultaneous with this final marketing approval, we plan to launch all strengths of Taztia. We believe that Taztia will be a significant contributor to Andrx's 2003 operating results."

Though FDA awarded Andrx's ANDA a 180-day period of marketing exclusivity, that exclusivity period has expired.

About Andrx

Andrx Corporation develops and commercializes: bioequivalent versions of controlled-release brand name pharmaceuticals, using its proprietary drug delivery technologies; bioequivalent versions of specialty, niche and immediate-release pharmaceutical products, including oral contraceptives; and brand name or proprietary controlled-release formulations of existing immediate-release or controlled-release drugs where it believes the application of Andrx's drug delivery technologies may improve the efficacy or other characteristics of those products. Andrx also has distribution operations which purchase primarily generic pharmaceuticals manufactured by third parties and utilize telemarketing sales representatives to sell these products, as well as its own, primarily to independent pharmacies, pharmacy chains that do not maintain their own central warehousing facilities, pharmacy buying groups and, to a lesser extent, physicians' offices.

This release and additional information about Andrx Corporation are also available on the Internet at: http://www.andrx.com.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "expect," "plan," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative or other variations thereof or comparable terminology is intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to, Andrx's ability to manufacture Taztia and its market acceptance, as described herein, as well as Andrx's results of operations. Andrx is also subject to other risks as detailed from time-to-time in the Company's filings with the Securities and Exchange Commission.